JP2023509793A5 - - Google Patents
Info
- Publication number
- JP2023509793A5 JP2023509793A5 JP2022542364A JP2022542364A JP2023509793A5 JP 2023509793 A5 JP2023509793 A5 JP 2023509793A5 JP 2022542364 A JP2022542364 A JP 2022542364A JP 2022542364 A JP2022542364 A JP 2022542364A JP 2023509793 A5 JP2023509793 A5 JP 2023509793A5
- Authority
- JP
- Japan
- Prior art keywords
- cdr
- seq
- optionally
- complex according
- nucleoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026033178A JP2026102665A (ja) | 2020-01-10 | 2026-03-03 | 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用 |
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062959776P | 2020-01-10 | 2020-01-10 | |
| US62/959,776 | 2020-01-10 | ||
| US202062965712P | 2020-01-24 | 2020-01-24 | |
| US62/965,712 | 2020-01-24 | ||
| US202062968383P | 2020-01-31 | 2020-01-31 | |
| US62/968,383 | 2020-01-31 | ||
| US202063055499P | 2020-07-23 | 2020-07-23 | |
| US63/055,499 | 2020-07-23 | ||
| US202063069063P | 2020-08-23 | 2020-08-23 | |
| US63/069,063 | 2020-08-23 | ||
| US202063132856P | 2020-12-31 | 2020-12-31 | |
| US63/132,856 | 2020-12-31 | ||
| PCT/US2021/012667 WO2021142234A1 (en) | 2020-01-10 | 2021-01-08 | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026033178A Division JP2026102665A (ja) | 2020-01-10 | 2026-03-03 | 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023509793A JP2023509793A (ja) | 2023-03-09 |
| JP2023509793A5 true JP2023509793A5 (cg-RX-API-DMAC7.html) | 2024-01-17 |
| JP7829488B2 JP7829488B2 (ja) | 2026-03-13 |
Family
ID=76788870
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542364A Active JP7829488B2 (ja) | 2020-01-10 | 2021-01-08 | 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用 |
| JP2026033178A Pending JP2026102665A (ja) | 2020-01-10 | 2026-03-03 | 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026033178A Pending JP2026102665A (ja) | 2020-01-10 | 2026-03-03 | 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230144436A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4087653A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7829488B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220125800A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115427108A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021206234A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022013686A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3163295A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL294479A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022008533A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021142234A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US20230111212A1 (en) * | 2020-01-10 | 2023-04-13 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2021154477A1 (en) | 2020-01-31 | 2021-08-05 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (tfr) antibody and uses thereof |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| AU2021414227A1 (en) * | 2020-12-31 | 2023-07-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| WO2023283623A1 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| CA3230796A1 (en) | 2021-09-01 | 2023-03-09 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof |
| US11833221B2 (en) | 2021-09-01 | 2023-12-05 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds for reducing DMPK expression |
| IL311507A (en) * | 2021-09-16 | 2024-05-01 | Dyne Therapeutics Inc | Dosing of muscle targeting complexes for the treatment of dystrophinopathy |
| JP2024546436A (ja) * | 2021-11-12 | 2024-12-24 | ダイン セラピューティクス,インコーポレーテッド | 顔面肩甲上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| WO2024257848A1 (ja) * | 2023-06-16 | 2024-12-19 | ルクサナバイオテク株式会社 | 遅発性中枢毒性が低減されているアンチセンスオリゴヌクレオチドの設計方法、及びその製造方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2283759T3 (es) * | 2002-01-18 | 2007-11-01 | Pierre Fabre Medicament | Anticuerpos anti-igf-ir y sus aplicaciones. |
| US20100016215A1 (en) * | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| CN104520324A (zh) * | 2012-02-24 | 2015-04-15 | 施特姆森特Rx股份有限公司 | Dll3调节剂及其使用方法 |
| US9610362B2 (en) * | 2012-03-16 | 2017-04-04 | Valerion Therapeutics, Llc | Antisense conjugates for decreasing expression of DMPK |
| JP6475167B2 (ja) * | 2012-12-21 | 2019-02-27 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ジスルフィド結合した多価mhcクラスiを含む多機能タンパク質 |
| US10647768B2 (en) * | 2014-05-29 | 2020-05-12 | Macrogenics, Inc. | Multi-chain polypeptide-containing tri-specific binding molecules |
| EP3353306A4 (en) * | 2015-09-25 | 2019-06-05 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| DK3473270T5 (da) * | 2016-06-20 | 2024-09-09 | Genahead Bio Inc | Konjugat af antistof-lægemiddel |
| TWI833178B (zh) * | 2016-12-26 | 2024-02-21 | 日商Jcr製藥股份有限公司 | 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體 |
| CN118638787A (zh) * | 2017-12-06 | 2024-09-13 | 艾维迪提生物科学公司 | 治疗肌萎缩和强直性肌营养不良的组合物和方法 |
| AU2019315593B2 (en) * | 2018-08-02 | 2026-05-21 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof |
| JP7858532B2 (ja) * | 2020-01-10 | 2026-05-14 | ダイン セラピューティクス,インコーポレーテッド | 筋肉標的複合体および筋肉の健康に関連する遺伝子のモジュレーションのためのその使用 |
| CN115427448A (zh) * | 2020-01-10 | 2022-12-02 | 达因疗法公司 | 肌肉靶向复合物及其用途 |
| CN122124274A (zh) * | 2020-01-10 | 2026-06-02 | 达因疗法公司 | 肌肉靶向复合物及其用于治疗面肩肱型肌营养不良的用途 |
| US20230111212A1 (en) * | 2020-01-10 | 2023-04-13 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US20230117883A1 (en) * | 2020-01-24 | 2023-04-20 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof in treating muscle atrophy |
| IL295022A (en) * | 2020-01-31 | 2022-09-01 | Dyne Therapeutics Inc | Antibody against transferrin receptor and uses thereof |
-
2021
- 2021-01-08 EP EP21738259.7A patent/EP4087653A4/en active Pending
- 2021-01-08 CN CN202180019691.8A patent/CN115427108A/zh active Pending
- 2021-01-08 CA CA3163295A patent/CA3163295A1/en active Pending
- 2021-01-08 IL IL294479A patent/IL294479A/en unknown
- 2021-01-08 BR BR112022013686A patent/BR112022013686A2/pt unknown
- 2021-01-08 JP JP2022542364A patent/JP7829488B2/ja active Active
- 2021-01-08 KR KR1020227027136A patent/KR20220125800A/ko active Pending
- 2021-01-08 WO PCT/US2021/012667 patent/WO2021142234A1/en not_active Ceased
- 2021-01-08 AU AU2021206234A patent/AU2021206234A1/en active Pending
- 2021-01-08 MX MX2022008533A patent/MX2022008533A/es unknown
- 2021-01-08 US US17/791,681 patent/US20230144436A1/en active Pending
-
2026
- 2026-03-03 JP JP2026033178A patent/JP2026102665A/ja active Pending